News

Traders are watching for the 80th event, data lock and topline results, while some are also speculating about potential M&A.

SELLAS Life Sciences (SLS) has surged 550% in the past year, driven by technical momentum and speculative trading. SLS currently has no revenue, with all products in development or clinical trials, making the stock highly speculative. Technical indicators are overwhelmingly bullish, but high short interest highlights significant risk. Sentiment is...

First Financial Bank also held 10,000 SLS shares, valued at $147,600.

Endpoint Area listed Nov. 30 as the expected catalyst timing for Sellas’ Phase 3 GPS trial.

SELLAS Life Sciences Group stock has surged over the past three years, yet its low overall value score and rich market multiples leave investors weighing a strong price run against signals that the shares may already be pricing in a lot of good news. A roughly 8.5x return over 3 years places SELLAS Life Sciences Group among the stronger movers in biotech, which can heighten the risk that expectations get ahead of fundamentals. Anticipation around the Phase 3 REGAL AML trial readout and...

Buyout chatter is building after change-of-control updates and a market-cap surge to over $1.5 billion.

In recent days, SELLAS Life Sciences Group updated employment and severance agreements for key executives while its Phase 3 REGAL trial in acute myeloid leukemia neared final overall survival analysis, with 78 of 80 required events reached. These enhanced change‑of‑control terms, combined with the late‑stage status of galinpepimut‑S and early‑stage CDK9 inhibitor SLS009, have intensified market discussion about potential acquisition interest and the company’s long‑term oncology...

SELLAS Life Sciences Group (NasdaqCM:SLS) has amended executive employment and severance agreements tied to a potential change in control. The move comes as the company approaches final analysis of its pivotal Phase 3 acute myeloid leukemia (AML) immunotherapy trial. These contract changes are increasing speculation around potential merger or acquisition activity involving SELLAS Life Sciences. SELLAS Life Sciences Group is drawing renewed investor attention as its updated change in control...

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the 10 Stocks Investors Are Chasing Right Now. SELLAS Life Sciences extended its winning streak to an 8th straight session on Monday to soar to a new record high, as investors resumed buying positions after hinting at a potential takeover. In intra-day trading, the stock rocketed […]

Sellas Life Sciences, BlackBerry, and Ouster rallied to 52-week highs on Monday as investors rotated into the companies amid positive catalysts.

Recently updated change-of-control terms also fueled buyout chatter by outlining executive payouts and full equity acceleration related to a change in control.

Is SLS a good stock to buy? We came across a bullish thesis on SELLAS Life Sciences Group, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on SLS. SELLAS Life Sciences Group, Inc.’s share was trading at $9.07 as of June 23rd. SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical […]

XBI, which includes both SLS and IBRX, is on track for its strongest monthly performance since December 2023.

Investor interest has focused on companies nearing key milestones, signing major partnerships, or improving their business outlook.

SLS short interest climbed to nearly 33% of the float as of June 15, compared to 28.4% at the beginning of the year.

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the 9 Stocks Winning by Double Digits. Sellas Life Sciences extended its winning streak to a 6th straight session on Thursday, climbing 14.83 percent to end at $10.53 apiece, following a regulatory filing that hinted at a potential acquisition. In a disclosure, Sellas Life Sciences Group […]

The company updated the severance agreements for three of its top executives, including the CEO.

We just covered the 10 Stocks That Will 10X According to Social Media. Sellas Life Sciences (NASDAQ:SLS) ranks #10 (see 5 Stocks That Will 10X According to Social Media). Number of Hedge Fund Investors: 13 Sellas Life Sciences (NASDAQ:SLS) is one of the top favorite stocks social media believes can 10x. It is a biotech […]

CEO Angelos Stergiou's equity award will vest over four years, increasing his ownership stake to 1.76 million shares.

Shareholders are set to vote on five proposals, including one to increase the number of shares available under the 2023 Equity Incentive Plan.

The United States market remained flat over the last week but has shown a strong performance with a 24% increase over the past year, and earnings are forecast to grow by 19% annually. In this context, identifying high growth tech stocks involves looking for companies that not only align with these optimistic earnings forecasts but also demonstrate robust innovation and adaptability in an ever-evolving industry landscape.

Sellas is seeking about $13 million in disputed GPS milestone payments related to Phase 3 development.

Sellas disclosed that it had 196.6 million shares of common stock outstanding as of June 2, 2026, according to an SEC filing.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was one of the stocks on Jim Cramer’s radar on Mad Money as he explained that many investors might be missing out on the market’s biggest winners. Responding to a caller’s question about the company, Cramer stated: Oh, this life science company that is, look, okay, so this is […]

In recent days, SELLAS Life Sciences Group drew attention as its CEO highlighted real-world data and prior Phase 2 results while the Phase 3 REGAL trial of GPS in AML moved to within two events of a topline readout. Investor interest was further amplified when CNBC’s Jim Cramer described SELLAS as “a great spec,” underscoring how imminent REGAL data and the progress of second AML candidate SLS009 are shaping perceptions of the company’s pipeline. We’ll now examine how the approaching REGAL...

CEO Angelos Stergiou said the trial's extended duration suggests patients are living longer than originally projected and said the company remains "very bullish."

Sellas believes GPS-treated AML patients could live longer than those receiving standard treatment, with a projected survival of about 12.6 months versus 8 months.

Sellas will participate Wednesday in TD Cowen’s Oncology Innovation Summit, marking the final major conference appearance ahead of the Regal data release.

The company plans to move quickly toward a pre-BLA meeting with the FDA and a potential filing if the REGAL trial reports positive results.

Retail speculation intensified as short interest in SLS climbed to a record high of 30.7% ahead of the final Regal catalyst.